據(jù)美國《世界日報》報道,，乳癌疫苗現(xiàn)在有突破性發(fā)展。美國華裔科學(xué)家林維仁(Weizen Wei)領(lǐng)導(dǎo)的團隊,，研究出可預(yù)防HER-2型乳癌分子增生的刺激免疫系統(tǒng)新疫苗,，已在老鼠身上實驗成功。瑞典的合作機構(gòu)并已進行癌末病人臨床試驗,。
美國癌癥研究學(xué)會的《癌癥研究》期刊9月15日刊出林維仁團隊的研究報告,，并廣獲歐美各媒體報道,。這個疫苗對現(xiàn)行hercepting治療癌藥已產(chǎn)生抗體，癌細胞重生的患者而言,，是一個希望,，可能預(yù)防HER-2型乳癌患者的HER-2癌分子再生。
林維仁是底特律韋恩州立大學(xué)(Wayne State University)醫(yī)學(xué)院卡門諾斯(Karmanos)癌癥研究所的免疫及微生物系教授,。她15日受訪時指出,，乳癌患者中，罹HER-2型乳癌者約占三成,。林維仁說,，人體正常細胞中，HER-2蛋白質(zhì)表現(xiàn)十分微量,，但在許多腫瘤細胞中,，尤其是乳癌細胞中，常?？梢园l(fā)現(xiàn)HER-2蛋白質(zhì)過度表現(xiàn),。
她的研究是將脫氧核醣核酸(DNA)疫苗打入老鼠肌肉細胞，快速的喚醒免疫系統(tǒng),，使其辨識HER-2分子,，并采取行動，讓免疫系統(tǒng)產(chǎn)生大量抗體,，對乳癌細胞中的HER-2 蛋白質(zhì)發(fā)動攻擊,，而正常細胞因為HER-2蛋白質(zhì)較少而躲過。
林維仁說,，她的團隊提供瑞典的合作機構(gòu),，進行乳癌第四期病人的初步臨床試驗，到目前為止并無發(fā)生直接副作用,。林維仁說，現(xiàn)在在動物體上實驗的結(jié)果雖然很不錯,，但從實驗到廣泛使用,，還有很長的路要走。林維仁強調(diào),，預(yù)防勝于治療,，鼓勵大家多吃蔬果、多做運動,，放松心情,。（生物谷Bioon.com）
生物谷推薦原始出處：
Cancer Research 68, 7502-7511, September 15, 2008. doi: 10.1158/0008-5472.CAN-08-1489
DNA Vaccination Controls Her-2+ Tumors that Are Refractory to Targeted Therapies
Paula J. Whittington, Marie P. Piechocki, Henry H. Heng, Jennifer B. Jacob, Richard F. Jones, Jessica B. Back, and Wei-Zen Wei
1 Department of Immunology and Microbiology, School of Medicine and 2 Karmanos Cancer Institute, Wayne State University, Detroit, Michigan
Her-2/neu+ tumor cells refractory to antibody or receptor tyrosine kinase inhibitors are emerging in treated patients. To investigate if drug resistant tumors can be controlled by active vaccination, gefitinib and antibody sensitivity of four neu+ BALB/c mouse mammary tumor lines were compared. Significant differences in cell proliferation and Akt phosphorylation were observed. Treatment-induced drug resistance was associated with increased chromosomal aberrations as shown by spectral karyotyping analysis, suggesting changes beyond neu signaling pathways. When mice were immunized with pneuTM encoding the extracellular and transmembrane domains of neu, antibody and T-cell responses were induced, and both drug-sensitive and drug-resistant tumor cells were rejected. In T-cell–depleted mice, drug-sensitive tumors were still rejected by vaccination, but drug-refractory tumors survived in some mice, indicating their resistance to anti-neu antibodies. To further test if T cells alone can mediate tumor rejection, mice were immunized with pcytneu encoding full-length cytoplasmic neu that is rapidly degraded by the proteasome to activate CD8 T cells without inducing antibody response. All test tumors were rejected in pcytneu-immunized mice, regardless of their sensitivity to gefitinib or antibody. Therefore, cytotoxic T lymphocytes activated by the complete repertoire of neu epitopes were effective against all test tumors. These results warrant Her-2 vaccination whether tumor cells are sensitive or resistant to Her-2–targeted drugs or antibody therapy.
